JP2005508318A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508318A5
JP2005508318A5 JP2003528493A JP2003528493A JP2005508318A5 JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5 JP 2003528493 A JP2003528493 A JP 2003528493A JP 2003528493 A JP2003528493 A JP 2003528493A JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003528493A
Other languages
English (en)
Japanese (ja)
Other versions
JP4269052B2 (ja
JP2005508318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/029232 external-priority patent/WO2003024395A2/en
Publication of JP2005508318A publication Critical patent/JP2005508318A/ja
Publication of JP2005508318A5 publication Critical patent/JP2005508318A5/ja
Application granted granted Critical
Publication of JP4269052B2 publication Critical patent/JP4269052B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003528493A 2001-09-14 2002-09-13 連結ビアリール化合物 Expired - Fee Related JP4269052B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32255601P 2001-09-14 2001-09-14
US33543401P 2001-11-30 2001-11-30
US37862702P 2002-05-07 2002-05-07
US38683302P 2002-06-06 2002-06-06
PCT/US2002/029232 WO2003024395A2 (en) 2001-09-14 2002-09-13 Linked biaryl compounds

Publications (3)

Publication Number Publication Date
JP2005508318A JP2005508318A (ja) 2005-03-31
JP2005508318A5 true JP2005508318A5 (enExample) 2006-01-05
JP4269052B2 JP4269052B2 (ja) 2009-05-27

Family

ID=27502245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528493A Expired - Fee Related JP4269052B2 (ja) 2001-09-14 2002-09-13 連結ビアリール化合物

Country Status (13)

Country Link
US (2) US6869975B2 (enExample)
EP (1) EP1435946B8 (enExample)
JP (1) JP4269052B2 (enExample)
KR (1) KR20040063897A (enExample)
CN (1) CN1585638A (enExample)
AU (1) AU2002336532C1 (enExample)
BR (1) BR0212512A (enExample)
CA (1) CA2460313C (enExample)
ES (1) ES2443642T3 (enExample)
IL (1) IL160845A0 (enExample)
MX (1) MXPA04002330A (enExample)
NZ (1) NZ531917A (enExample)
WO (1) WO2003024395A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
IL160845A0 (en) * 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US20060258683A1 (en) * 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2005012221A1 (ja) * 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2007536341A (ja) * 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
WO2005105736A1 (en) * 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) * 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
DE602005020313D1 (de) * 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
AU2005311826A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
EP1819673A2 (en) * 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
FR2880886B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005020230A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
DE102005020229A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
US20090118337A1 (en) * 2005-06-03 2009-05-07 Davis Pamela B Methods and compositions for treating inflammation
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
US20090054435A1 (en) * 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
CA2621275A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
CA2621474A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1,3-disubstituted indole derivatives for use as ppar modulators
EA201101085A1 (ru) * 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
CN102014897B (zh) 2008-04-21 2015-08-05 西格纳姆生物科学公司 化合物、组合物和其制备方法
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2012007927A (es) * 2010-01-06 2012-08-15 Panmira Pharmaceuticals Llc Antagonistas de dp2 y usos del mismo.
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
CN113912547B (zh) 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
CA3185909A1 (en) 2020-07-22 2022-01-27 Reneo Pharmaceuticals, Inc. Crystalline ppar-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038934A (en) * 1959-03-17 1962-06-12 Smith Kline French Lab Iodinated 4-(4'-alkoxyphenoxy)phenylpropionic acids
US4443536A (en) * 1981-08-25 1984-04-17 Eastman Kodak Company Nondiffusible photographic couplers and photographic elements and processes employing same
US4466902A (en) * 1982-01-31 1984-08-21 Ipposha Oil Industries, Co., Ltd. Rust inhibitor
DE68923591T2 (de) * 1988-09-14 1996-03-28 Eastman Kodak Co Photographisches Aufzeichnungsmaterial mit Magenta-Kuppler und einem Chalcogenazoliumsalz.
AU2952695A (en) 1994-07-01 1996-01-25 Salk Institute For Biological Studies, The Mammalian peroxisome proliferator-activated receptors and uses thereof
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
CA2245524A1 (en) 1996-02-02 1997-08-07 Wei Han Antidiabetic agents
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
ES2191284T3 (es) * 1997-03-27 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de 2-fenoxianilina.
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6346639B1 (en) 1997-12-23 2002-02-12 The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization Boronic compounds
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
KR100682276B1 (ko) * 1998-07-24 2007-02-28 데이진 가부시키가이샤 안트라닐산 유도체
JP2003500432A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
EP1194146B1 (en) 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2001000579A1 (en) 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
EP1210345B1 (en) 1999-09-08 2004-03-03 Glaxo Group Limited Oxazole ppar antagonists
JP2003523336A (ja) 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
HK1052351B (en) 2000-06-28 2006-11-03 Japan Tobacco Inc. Benzothiazolyl ppar-gamma modulators
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
JP4790969B2 (ja) 2000-08-11 2011-10-12 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
GB0024362D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1357914A2 (en) 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
DE60233111D1 (de) * 2001-02-14 2009-09-10 Karobio Ab Glucocorticoid-rezeptoren-modulatoren
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
JP4157381B2 (ja) 2001-03-23 2008-10-01 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体の活性化剤
KR20040027927A (ko) * 2001-08-24 2004-04-01 카로 바이오 아베 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
KR100913269B1 (ko) * 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
CA2473162A1 (en) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Similar Documents

Publication Publication Date Title
CA2460313A1 (en) Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels
TWI339121B (en) 1-piperazine- and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic application thereof
CN102030700B (zh) 苯甲酰胺基羧酸类化合物及其制法和药物用途
JP6579103B2 (ja) ハロゲン置換へテロ環化合物の塩
US5606073A (en) Diazole-propenoic acid compounds
SG192439A1 (en) Organic compounds
JP2010526807A5 (enExample)
TW200815422A (en) Heteroaryl derivatives as cytokine inhibitors
JP2009513703A5 (enExample)
JP2004529161A5 (enExample)
TW200901996A (en) Inhibitors of focal adhesion kinase
CN111285829A (zh) 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途
WO2010069124A1 (zh) 酰胺基噻唑衍生物及其制备方法和用途
WO2004091610A1 (en) Imidazole derivatives for treatment of allergic and hyperproliferative disorders
AU2015336458A1 (en) KCNQ2-5 channel activator
CN101068784A (zh) 间烟碱化合物的羟基苯甲酸盐
CN108727295A (zh) 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
JP2010531322A (ja) アントラニルアミドピリジンウレア及びベンズアミド誘導体の相乗組合せ
JPWO2001036402A1 (ja) 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP2009506127A (ja) 糖尿病の処置に有用なアニリノピラゾール誘導体
CN112739680A (zh) Dp拮抗剂
JP2011516445A (ja) Ｈｄｌ−コレステロール上昇剤としての３−トリフルオロメチル−ピラジン−２−カルボン酸アミド誘導体
CN112625026B (zh) Tam家族激酶抑制剂的喹啉衍生物
WO2002006249A1 (en) Method for producing 1-substituted-1,2,3-triazole derivative
CN106117182A (zh) 喹唑啉‑n‑苯乙基四氢异喹啉类化合物及其制备方法和应用